Aptose Biosciences Inc. (TSE:APS) (NASDAQ:APTO)’s stock price crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $8.04 and traded as low as $7.55. Aptose Biosciences shares last traded at $7.67, with a volume of 22,396 shares traded.

APS has been the subject of a number of research reports. Alliance Global Partners reiterated a “buy” rating and issued a C$12.00 price target on shares of Aptose Biosciences in a research note on Tuesday, September 22nd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Aptose Biosciences in a research note on Monday, October 19th.

The firm has a market capitalization of $681.57 million and a price-to-earnings ratio of -11.82. The stock has a 50 day moving average of C$7.07 and a 200 day moving average of C$8.04. The company has a quick ratio of 24.38, a current ratio of 24.60 and a debt-to-equity ratio of 0.93.

Aptose Biosciences Company Profile (TSE:APS)

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Read More: What sectors are represented in the Hang Seng index?

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.